AI-Accelerated Cyclic Peptide Library Design & Customization
Target-informed library composition, scaffold diversity, virtual prioritization and selection of candidates for a focused discovery campaign.
Explore library design service →AI-Enabled Cyclic Peptide Discovery
Connect target insight, macrocycle discovery, oral developability and experimental evidence in one project-specific workflow.
Explore the Workflow →Macrocyclic Peptide Services
Our services connect target and binding-interface assessment, cyclic peptide hit discovery, oral developability optimization, modality design, and experimental feedback. Each project starts from the evidence available—whether a target, a screening hit, or an established peptide scaffold—and defines the next decision before selecting computational and experimental work.
Explore the service groups below, or follow the IL-23R example to see how a target-focused oral macrocyclic peptide program can be structured. The example describes work we can scope with a client; it does not represent an internally generated IL-23R asset or clinical outcome.
01 / Discovery & Hit Finding
Assess the target surface and binding interface, define differentiating regions and design a focused or diverse macrocyclic peptide library for virtual prioritization and subsequent screening.
Target-informed library composition, scaffold diversity, virtual prioritization and selection of candidates for a focused discovery campaign.
Explore library design service →Analyze protein–protein interfaces, plausible binding hotspots and selectivity questions to guide cyclic peptide concepts for extracellular or intracellular PPIs.
Explore PPI inhibitor design →02 / Oral Design & Developability
Two valid entry points are redesigning an active peptide for oral exposure, or selecting a permeability- and stability-oriented scaffold before adding target-binding features. The appropriate path depends on starting evidence and the trade-offs measured in the project.
Generate and compare sequences, stereochemistry and conformational constraints against activity and oral-property objectives.
Explore oral design →Prioritize permeability-related features while distinguishing membrane or intestinal assay results from measured oral bioavailability.
Explore permeability assessment →Compare defined absorption, stability, distribution and clearance hypotheses with stated model applicability and a plan for empirical calibration.
Explore ADMET prediction →Rank hit-to-lead modifications jointly for potency, selectivity, permeability, metabolic stability and synthesis risk.
Explore lead optimization →Compare alternative cyclic frameworks around an existing hit while testing whether binding features and developability are retained.
Explore scaffold hopping →Evaluate attachment sites and albumin-binding motifs against receptor activity, free fraction, exposure and route-of-administration goals. Scope the chemistry and PK evidence before offering a dedicated program.
Explore service →03 / Targeting & Modality Design
Connect target-binding design with cellular entry and intracellular functional readouts where the target is inside the cell.
Explore intracellular targeting →Consider peptide recognition elements, conjugation positions, linkers and payload-related constraints.
Explore PDC design →Assess an oral PDC concept case by case; conjugation does not itself establish oral feasibility.
Explore oral PDC design →Explore binding geometry and developability trade-offs when multiple recognition functions are required.
Explore multispecific design →Assess cyclization site, ring size, bicyclic topology, precursor sequence and chemistry-specific risks before committing to synthesis. A focused pilot and experimental feedback define the supported design space.
Explore service →Plan structural confirmation and project-specific binding, function, permeability, stability or PK assays to answer defined candidate-selection questions.
Explore experimental validation →Illustrative Project Workflow

For a client exploring IL-23R antagonism, the following sequence links design choices to specific evidence. Stages can be commissioned together or separately, depending on available target data, known peptides and experimental capacity.
Review IL-23R biology, structural information, ligand-binding surfaces and differentiation hypotheses; define the desired mechanism and selection criteria. See PPI inhibitor design.
Build a target-informed virtual library, compare ring constraints and binding hypotheses, then nominate a focused screening set. Starting from a known peptide, compare alternative frameworks with scaffold hopping. See library design.
Iterate affinity and selectivity alongside conformational behavior, permeability-related properties, solubility and metabolic stability; rank candidates with uncertainty visible. See oral design, permeability, ADMET and lead optimization.
Compare attachment positions and albumin-binding concepts with receptor activity and oral-exposure objectives. This planned module requires a chemistry-specific feasibility review; longer systemic half-life alone does not demonstrate improved oral absorption.
Review proposed cyclization topology and synthesis risk; produce a prioritized set for structural confirmation, IL-23R binding and functional tests, plus permeability, stability and PK work where scoped. Feed measured results into the next design round. See experimental validation.
IL-23R is used here as a public-domain example of a possible service workflow. Any study design, assay availability, deliverables and claims of performance require project-specific confirmation.
Share a target, existing hit or peptide scaffold and the question your team needs to resolve. We can propose a focused combination of computational design and validation services.
Discuss a project →Submit your project details below, and our team will respond within 24 hours.